[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2099451T3 - Kombinacja inhibitora HDAC oraz antymetabolitu - Google Patents

Kombinacja inhibitora HDAC oraz antymetabolitu

Info

Publication number
PL2099451T3
PL2099451T3 PL07862420T PL07862420T PL2099451T3 PL 2099451 T3 PL2099451 T3 PL 2099451T3 PL 07862420 T PL07862420 T PL 07862420T PL 07862420 T PL07862420 T PL 07862420T PL 2099451 T3 PL2099451 T3 PL 2099451T3
Authority
PL
Poland
Prior art keywords
antimetabolite
combination
hdac inhibitor
hdac
inhibitor
Prior art date
Application number
PL07862420T
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2099451(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2099451T3 publication Critical patent/PL2099451T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07862420T 2006-12-04 2007-11-30 Kombinacja inhibitora HDAC oraz antymetabolitu PL2099451T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04
PCT/US2007/024712 WO2008070011A2 (en) 2006-12-04 2007-11-30 Combination of an hdac inhibitor and an antimetabolite
EP07862420.2A EP2099451B1 (en) 2006-12-04 2007-11-30 Combination of an hdac inhibitor and an antimetabolite

Publications (1)

Publication Number Publication Date
PL2099451T3 true PL2099451T3 (pl) 2016-07-29

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07862420T PL2099451T3 (pl) 2006-12-04 2007-11-30 Kombinacja inhibitora HDAC oraz antymetabolitu

Country Status (26)

Country Link
US (1) US8093220B2 (pl)
EP (1) EP2099451B1 (pl)
JP (3) JP5784274B2 (pl)
KR (1) KR101475538B1 (pl)
CN (1) CN101553223A (pl)
AR (1) AR064072A1 (pl)
AU (1) AU2007328281B2 (pl)
BR (1) BRPI0719746A2 (pl)
CA (1) CA2670741C (pl)
CL (1) CL2007003467A1 (pl)
EC (1) ECSP099483A (pl)
ES (1) ES2569477T3 (pl)
GT (1) GT200900148A (pl)
HK (1) HK1132462A1 (pl)
IL (1) IL198638A (pl)
MA (1) MA30982B1 (pl)
MX (1) MX2009005946A (pl)
MY (1) MY148893A (pl)
NO (1) NO20092473L (pl)
PE (1) PE20081303A1 (pl)
PL (1) PL2099451T3 (pl)
RU (1) RU2469717C2 (pl)
TN (1) TN2009000213A1 (pl)
TW (1) TW200831075A (pl)
WO (1) WO2008070011A2 (pl)
ZA (1) ZA200903041B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5330498B2 (ja) * 2008-03-26 2013-10-30 ノバルティス アーゲー 脱アセチル化酵素ｂのヒドロキサメートを基にした阻害剤
MX2011000719A (es) * 2008-07-18 2011-03-01 Novartis Ag Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de enfermedad de hodgkin.
WO2010009285A1 (en) * 2008-07-18 2010-01-21 Novartis Ag Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
NZ707377A (en) * 2010-06-07 2015-09-25 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CN103079551A (zh) * 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
US9757385B2 (en) 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
ES2751464T3 (es) 2014-09-17 2020-03-31 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
CR20170420A (es) 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20070123580A1 (en) * 2003-05-21 2007-05-31 Atadja Peter W Combination of histone deacetylase inhibitors with chemotherapeutic agents

Also Published As

Publication number Publication date
AU2007328281B2 (en) 2011-03-31
JP5784274B2 (ja) 2015-09-24
PE20081303A1 (es) 2008-10-28
ECSP099483A (es) 2009-08-28
CA2670741C (en) 2016-04-12
KR20090087115A (ko) 2009-08-14
US20100069318A1 (en) 2010-03-18
JP2014097992A (ja) 2014-05-29
US8093220B2 (en) 2012-01-10
NO20092473L (no) 2009-09-01
RU2009125439A (ru) 2011-01-20
CA2670741A1 (en) 2008-06-12
ZA200903041B (en) 2010-03-31
MX2009005946A (es) 2009-06-17
BRPI0719746A2 (pt) 2013-12-10
JP2016006070A (ja) 2016-01-14
TN2009000213A1 (en) 2010-10-18
AR064072A1 (es) 2009-03-11
JP2010511702A (ja) 2010-04-15
EP2099451A2 (en) 2009-09-16
KR101475538B1 (ko) 2014-12-22
WO2008070011A3 (en) 2008-07-24
ES2569477T3 (es) 2016-05-11
MA30982B1 (fr) 2009-12-01
IL198638A0 (en) 2010-02-17
HK1132462A1 (zh) 2010-02-26
AU2007328281A1 (en) 2008-06-12
WO2008070011A2 (en) 2008-06-12
CL2007003467A1 (es) 2008-07-11
TW200831075A (en) 2008-08-01
RU2469717C2 (ru) 2012-12-20
IL198638A (en) 2015-06-30
CN101553223A (zh) 2009-10-07
EP2099451B1 (en) 2016-02-10
GT200900148A (es) 2011-08-02
MY148893A (en) 2013-06-14

Similar Documents

Publication Publication Date Title
IL198638A0 (en) Combination of an hdac inhibitor and an antimetabolite
SI2295410T1 (sl) Inhibitor za HDAC
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
HK1161583A1 (en) Deacetylase inhibitors and uses thereof
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL196462A0 (en) Substituted acylanilides and methods of use thereof
IL197185A0 (en) Substituted acylanilides and methods of use thereof
HK1138833A1 (en) Carboxamide compounds and their use as calpain inhibitors
HK1146792A1 (en) Parp inhibitor compounds, compositions and methods of use parp
PL2027096T3 (pl) Podstawione aryloimidazolony oraz triazolony jako inhibitory receptorów wazopresyny
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GB0622084D0 (en) Inhibitors of HSP90
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
IL192319A0 (en) Assessment of medical conditions
ZA200804681B (en) Inhibitors of C-Met and uses thereof
GB0624187D0 (en) HDAC inhibitors
TWI370812B (en) Ester compound and its use
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
GB0604901D0 (en) Improved formulation of COMT inhibitors
GB0608822D0 (en) Inhibitors of DHFR
GB0621103D0 (en) Inhibitors of MEK